In-vivo measurement of activated microglia in dementia

Annachiara Cagnin, David J. Brooks, Angus M. Kennedy, Roger N. Gunn, R. Myers, Federico E. Turkheimer, Terry Jones, Richard B. Banati

    Research output: Contribution to journalArticlepeer-review


    Background Activated microglia have a key role in the brain's immune response to neuronal degeneration. The transition of microglia from the normal resting state to the activated state is associated with an increased expression of receptors known as peripheral benzodiazepine binding sites, which are abundant on cells of mononuclear phagocyte lineage. We used brain imaging to study expression of these sites in healthy individuals and patients with Alzheimer's disease. Methods We studied 15 normal individuals (age 32-80 years), eight patients with Alzheimer's disease, and one patient with minimal cognitive impairment. Quantitative in-vivo measurements of glial activation were obtained with positron emission tomography (PET) and carbon-11-labelled (R)-PK11195, a specific ligand for the peripheral benzodiazepine binding site. Findings In normal individuals, regional [ 11C](R)-PK11195 binding did not significantly change with age, except in the thalamus, where an age-dependent increase was found. By contrast, patients with Alzheimer's disease showed significantly increased regional [ 11C](R)-PK11195 binding in the entorhinal, temporoparietal, and cingulate cortex. Interpretation In-vivo detection of increased [ 11C](R)-PK11195 binding in Alzheimer-type dementia, including mild and early forms, suggests that microglial activation is an early event in the pathogenesis of the disease.
    Original languageEnglish
    Pages (from-to)461-467
    Number of pages6
    JournalThe Lancet
    Issue number9280
    Publication statusPublished - 11 Aug 2001


    Dive into the research topics of 'In-vivo measurement of activated microglia in dementia'. Together they form a unique fingerprint.

    Cite this